The Japanese pharma is aiming for $1.3 billion in yearly savings between now and 2030. Elsewhere, Datroway gained a new clearance in breast cancer and the FDA approved a drug for hepatitis D.
An article from
News roundup
The Japanese pharma is aiming for $1.3 billion in yearly savings between now and 2030. Elsewhere, Datroway gained a new clearance in breast cancer and the FDA approved a drug for hepatitis D.
Published May 26, 2026
Getty Images
AstraZeneca, Daiichi beat Gilead to first-line TNBC with FDA nod for Datroway
EU and US advisers split over AstraZeneca breast cancer drug
Fierce Pharma Asia—Merck-Kelun ADC’s triple wins; Tools in China licensing deals; Takeda’s $885M antitrust loss
Amgen's Tavneos, facing liver injury scrutiny, gets label update in Japan as patient starts resume
Astellas’ five-year plan includes chasing record sales and cost cuts
Europe's CHMP gives thumbs up to AZ's breast cancer drug after thumbs down from FDA adcomm
Five biotech news updates to stay on top of today
Astellas Announces Five-Year Corporate Strategic Plan to Deliver Greater VALUE Faster for Patients and Position Itself as a Sustainable Growth Company
Immunovant shares surge on arthritis trial data
New data show VEGF bispecifics could compete with Summit, Akeso drug
Alzheimer's drug rollout letdown, a China-based heart drug startup, and more biotech news from The Readout
Avalo reported study success in what’s proven to be a tough-to-treat skin disease. Elsewhere, BioNTech announced plans to close…
The TROP2 battle in first-line triple-negative breast cancer has officially kicked off. | A three-way battle among TROP2 ADCs in…
Merck-Kelun ADC outperforms Keytruda in trial, a closely watched Parkinson’s drug fails, and more biotech news from The Readout
The agency has once again shuffled the leadership for two top drug review offices. Elsewhere, Parabilis partnered with Regeneron…
Bristol Myers Squibb and Hengrui Pharma signed a massive deal worth up to $15.2 billion. Takeda aims to cut 4,500 jobs in fiscal…
